← Eichor
Study identifier: NCT04844060 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cerebro Spinal Fluid Collection (CSF)

Condition: Alzheimer Disease · Dementia With Lewy Bodies · Frontotemporal Dementia  ·  Sponsor: University Hospital, Strasbourg, France

PhaseN/A
Planned participants10000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Cognitive neurodegenerative diseases are a major public health issue. At present, the diagnosis of certainty is still based on anatomopathological analyses. Even if the diagnostic tools available to clinicians have made it possible to improve probabilistic diagnosis during the patient's lifetime, there are still too many diagnostic errors and sub-diagnostic in this field. The arrival of biomarkers has made it possible to reduce these diagnostic errors, which were of the order of 25 to 30%. This high error rate is due to different parameters. These diseases are numerous and often present common symptoms due to the fact that common brain structures are affected. These diseases evolve progressively over several years and their early diagnosis, when the symptoms are discrete, makes them even more difficult to diagnose at this stage. In addition, co-morbidities are common in the elderly, further complicating the diagnosis of these diseases. At present, the only cerebrospinal fluid (CSF) biomarkers that are routinely used for the biological diagnosis of neurodegenerative cognitive pathologies are those specific to Alzheimer's disease: Aβ42, Aβ40, Tau-total and Phospho-Tau. These biomarkers represent an almost indispensable tool in the diagnosis of dementia. It is therefore important to determine whether Alzheimer's biomarkers can be disrupted in other neurodegenerative cognitive pathologies, but also to find biomarkers specific to these different pathologies by facilitating the i…

This description comes directly from the study's public registry record.

Talk to the study team

Frédéric BLANC, MD/PhD  ·  33388155858  ·  frederic.blanc@unistra.fr

Olivier BOUSIGES, PharmD/PhD  ·  33388128909 / 33368854039  ·  olivier.bousiges@chru-strasbourg.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Service d'évaluation et Centre Mémoire de Ressources et de Recherche (CM2R), Hôpital de jour Saint François - Pôle de Gériatrie, Hôpitaux Universitaires de Strasbourg, Hôpital de la RobertsauStrasbourg, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04844060